Lenalidomide-OH, a hydroxylated analog of Lenalidomide which is a cereblon (CRBN) ligand used for
E3 ubiquitin ligase, can be used as a E3 ligase ligand in PROTACs for the recruitment of CRBN protein. Specifically, Lenalidomide-OH can be connected via a linker to the warhead in PROTACs that target a protein for degradation. Lenalidomide (also known as Revlimid,
CC-5013) is a derivative of thalidomide approved in the United States
in 2005 for the treatment for myeloma and blood disorders called
myelodysplastic syndromes.